Genmab sees big potential in epcoritamab – expects EU approval this year

CEO Jan van de Winkel considers it a milestone that the second Genmab-owned product is now on the US market.
Photo: Bidstrup Stine/Ritzau Scanpix
Photo: Bidstrup Stine/Ritzau Scanpix
by MARKETWIRE, translated by kristoffer grønbæk & daniel pedersen

Genmab takes an important step forward by winning US approval for epcoritamab, which can now be used for third-line treatment of diffuse large B cell lymphoma (DLBCL).

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading